1 |
Braud, E. M., Nourrisson, M. R., Tonnerre, A., Picot, C., LeBaut, G., Renard, P., Pfeiffer, B., and Tucker, G., Potential Inhibitors of angiogenesis. Part I: 3-(imidazolyl-4 (5)-ylmethylene) indolin-2-ones. J. Enzyme Inhib. Med. Chem., 18, 243-252 (2003)
DOI
ScienceOn
|
2 |
Coda, A. C., Invernizzi, A. G., Righetti, P. P., and Tacconi, G., (Z)- and (E)-Arylindene-1,3-dihydro indol-2-ones: configuration, conformation, and infrared carbonyl stretching frequencies. J. Chem. Soc. Perkin Trans, 2, 615-619 (1984)
|
3 |
Cortes-Funes, H., Antiangiogenic agents. Drugs of Today, 38, 11-19 (2002)
|
4 |
Ewing T. J. A., Makino, S., Skillman, A. G., and Kuntz, I. D., Dock 4.0: Search strategies for automated molecular docking flexible molecule databases. J. Comp.-Aid. Mol. Des., 15, 411-428 (2001)
DOI
ScienceOn
|
5 |
Fabbro, D., Parkinson, D., and Matter, A., Protein tyrosine kinase inhibitors: new treatment modalities. Curr. Opin. Pharmacol. 2, 374-381 (2002)
DOI
ScienceOn
|
6 |
Fong, T. A. T., Shawver, L. K., App, H., Sun, L., Tang, C., Rice, A., Kim, Y. H., Schreck, R., Chen, J., Dowd, B., Suto, E., Vasile, S., Wang, X., Hirth, K. P., and McMahon, G., SU 5416: a potent and selective Flk-1/KDR kinase inhibitor that blocks Flk-1 phosphorylation, endotelhial cell mitogenesis, and tumor growth. Proc. Am. Assoc. Cancer Res., 39, 560-567 (1998)
|
7 |
Fong, T. A. T., Shawer, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G., SU 5416: is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth for multiple tumor types. J. Cancer Res., 59, 99-106 (1999)
|
8 |
Roussidis, A. E. and Karamanos, N. K., Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment. In vivo, 16, 459-470 (2002)
|
9 |
Taylor, V. C., Buckley, C. D., Douglas, M., Cody, A. J., Simmons, D. L., and Freeman, S. D., The myeloid-specific sialic acid binding receptor, CD33, associated with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem., 274, 11505-11512 (1999)
DOI
ScienceOn
|
10 |
Olgen, S., Akaho, E., and Nebioglu, D., Synthesis and antityrosine activity of 3-(substituted-benzylidene)-1, 3-dihydroindolin derivatives: investigation of their role against receptor tyrosine kinase with the application of receptor docking studies. Farmaco, 60, 497-506 (2005)
DOI
ScienceOn
|
11 |
Traxler, P. and Lyndon, N., Recent advances in protein tyrosine kinase inhibitors. Drugs of the Future, 20, 1261-1274 (1995)
DOI
|
12 |
Rewcastle, G. W., Palmer, B. D., Dobrusin, E. M., Fry, D. W., Kraker, A. J., and Denny, W. A., Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2, 2'-dithiobis (1-methyl-N-phenyl-1H-indole-3-carboxamide). J. Med. Chem., 37, 2033-2042 (1994)
DOI
ScienceOn
|
13 |
Folkman, J., Tumor angiogenesis. Adv. Cancer Res., 43, 175- 203 (1985)
DOI
|
14 |
Terrence, R. B., Protein-tyrosine kinase inhibitors. Drugs of the Future, 17, 119-131 (1992)
|
15 |
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connelly, P. A., Discovery of a novel, potent and src family selective tyrosine kinase inhibitor. J. Biol. Chem., 271, 695-701 (1996)
DOI
|
16 |
Ewing T. J. A. and Kuntz, I. D., Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem., 18, 1175-1189 (1997)
DOI
ScienceOn
|
17 |
Lyne, P. D., Structure-based virtual screening: an overview. Drug Discovery Today, 7, 1047-1055 (2002)
DOI
ScienceOn
|
18 |
Noonberg, S. B. and Benz, C. C., Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs, 59, 753-767 (2000)
DOI
ScienceOn
|
19 |
Thompson, A. M., Rewcastle, G. W., Boushelle, S. L., Hartl, B. G., Kraker, A. J., Lu, G. H., Batley, B. L., Panek, R. L., Showalter, H. D. H., and Denny, W. A., Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1, 6- naphthydrin-2 (1H)-ones as selective inhibitors of . J. Med. Chem., 43, 3134-3147 (2000)
DOI
ScienceOn
|
20 |
Sun, Y, Ewing T. J. A., Skillman, A. G., and Kuntz, I. D., CombiDOCK: Structure-based combinatorial docking and library design. J. Comp.-Aid. Mol. Des., 12, 597-604 (1998)
DOI
ScienceOn
|
21 |
Khols, D. W. D., Fry, D. W., and Kraker, A. J., Inhibitors of tyrosine kinase. Curr. Opin. Oncol., 9, 562-568 (1997)
DOI
|
22 |
Zhu, X., Kim, J. L., Newcomb, J. R., Rose, P. E., Stover, D. R., Toledo, L. M., Zhao, H., and Morgenstern, K. A., Structural Analysis of the Lymphocyte-Specific Kinase Lck in Complex with Non-Selective and Src Family Selective Kinase. Structure, 7, 651-661 (1999)
DOI
ScienceOn
|
23 |
Hamby, J. M. and Showalter, H. D. H., Small molecule inhibitors of tumor promoted angiogenesis, including protein kinase inhibitors. Pharmacol. Ther., 82, 169-193 (1999)
DOI
ScienceOn
|
24 |
Sun, L., Tran, N., Liang, C., Tang, F., Rice, A., Schreck, R., Waltz, K., Shaever, L. K., McMahon, G., and Tang, C., Design, synthesis and evaluations of substituted 3-[(3- or 4- carboxy ethyl pyrrol-2-yl)methylindenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J. Med. Chem., 42, 5120-5130 (1999)
DOI
ScienceOn
|
25 |
Sun, L., Tran, N., Liang, C., Hubbard, S., Tang, F., Lipson, K., Schreck, R., Zhou, Y., McMahon, G., and Tang, C., Identification of substituted 3-[(4, 5, 6, 7-Tetrahydro-1H-indole-2-yl) methylene]-1, 3-hydroindole-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rb tyrosine kinases. J. Med. Chem., 43, 2655-2663 (2000)
DOI
ScienceOn
|
26 |
Taylor, R. D., Jewsbury, P. J., and Essex, J. W., A review of protein-small molecule docking methods. J. Comp.-Aid. Mol. Des., 16, 151-166 (2002)
DOI
ScienceOn
|
27 |
Akaho, E., Fujikawa, C., Runion, H. I., Hill, C. R., and Nakaho, H., A study on docking mode of hiv protease and their inhibitors. J. Chem. Software, 5, 147 -162 (1999)
DOI
|
28 |
Meng, E. C., Scoichet, B. K., and Kuntz, I. D., Automated docking with grid-base evaluation. J. Comput. Chem., 13, 505-524 (1992)
DOI
|
29 |
Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., and Schlessinger, J., Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955-960 (1997)
DOI
ScienceOn
|
30 |
Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., and Tang, C., Synthesis and biological evaluations of 3- substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular tyrosine kinases. J. Med. Chem., 41, 2588-2603 (1998)
DOI
ScienceOn
|
31 |
Levitzki, A. and Grazit, A., Tyrosine kinase inhibition: an approach to drug development. Science, 267, 1782-1788 (1995)
DOI
|
32 |
Folkman, J., Anti-angiogenesis: new concepts for theraphy of solid tumors. Ann. Surg., 175, 409-416 (1972)
DOI
ScienceOn
|
33 |
Kuntz, I. D., Dock. 4.0 (University of California, San Francisco Web Site) (1998)
|
34 |
Olgen, S., Akaho, E., and Nebioglu, D., Evaluation of indole esters as inhibitors of receptor tyrosine kinase and investigation of the inhibition using receptor docking studies. J. Enzy. Inhib. Med. Chem. 18, 485-490 (2003)
DOI
ScienceOn
|
35 |
Widler, L., Green, J., Missbach, M., Susa, M., and Altmann, E., 7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2, 3-d]pyrimidinespotent inhibitors of the tyrosine kinase c-Src. Bioorg. Med. Chem. Lett., 11, 849-852 (2001)
DOI
ScienceOn
|
36 |
Schulz-Gasch, T. and Stahl, M., Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J. Mol. Model., 9, 47-57 (2003)
DOI
|